Please login to the form below

vildagliptin

This page shows the latest vildagliptin news and features for those working in and with pharma, biotech and healthcare.

Novartis to make 15 drugs available at $1 a month

Among the drugs to be made available under the scheme are high blood pressure medicine valsartan, tamoxifen for breast cancer and vildagliptin for diabetes.

Latest news

AZ sues to block generic saxagliptin from Mylan

world market for DPP4 inhibitors, a class which also includes Merck &Co's market-leading Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Boehringer Ingelheim/Lilly's Trajenta (linagliptin).
Pfizer still number one - just

Meanwhile, Novartis kept the pressure on with solid performances for its own new entrants, including Gilenya (fingolimod) for multiple sclerosis, cancer drugs Afinitor/Votubia (everolimus) and Tasigna (nilotinib) and Galvus (vildagliptin)
NICE turns down Afinitor for breast cancer

for leukaemia, Galvus (vildagliptin) for diabetes and blood cancer therapy Jakavi (ruxolitinib).
Novartis lifts 2013 guidance on delay to Diovan generics

Gilenya (fingolimod), Afinitor (everolimus) for breast cancer, leukaemia therapy Tasigna (nilotinib) and Galvus (vildagliptin) for diabetes just about offsetting revenue losses to generic competition of some $800m in the quarter.
Setback for AZ and BMS as Onglyza flunks cardiovascular trial

vildagliptin). The trial was set up in the wake of new US FDA guidelines in 2009 which required pharma companies to perform cardiovascular outcome studies on new diabetes drugs.

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest appointments

bmore creative hires Kush Rach as new business director

He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editorial Director – Medical Education – Oxford: Negotiable

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Scientific Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor – Medical Education Agency – Bucks: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Senior Programme Executive: Salary TBC

Senior Medical Writer: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...